The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs
Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis. To establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin re...
Uloženo v:
| Vydáno v: | Health technology assessment (Winchester, England) Ročník 25; číslo 16; s. 1 - 62 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
NIHR Journals Library
01.03.2021
|
| Témata: | |
| ISSN: | 1366-5278, 2046-4924, 2046-4924 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis.
To establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin related.
A series of 200 double-blinded N-of-1 trials.
Participants were recruited from 50 general practices in England and Wales.
Patients who were considering discontinuing statin use and those who had discontinued statin use in the last 3 years because of perceived muscle symptoms.
Participants were randomised to a sequence of six 2-month treatment periods during which they received 20 mg of atorvastatin daily or a matched placebo.
The primary outcome was self-reported muscle symptoms rated using a visual analogue scale on the last week of each treatment period. Secondary outcomes included the participant's belief about the cause of their muscle symptoms, the site of muscle symptoms, how the muscle symptoms affected the participant, any other symptoms they experienced, adherence to medication, the participant's decision about statin treatment following the trial, and whether or not they found their own trial result helpful.
A total of 151 out of 200 (75.5%) randomised participants provided one or more visual analogue scale measurements in a placebo period and one or more measurements in a statin period, and were included in the primary analysis. There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14;
= 0.398). Withdrawals, adherence and missing data were similar during the statin periods and the placebo periods.
Among people who previously reported severe muscle symptoms while taking statins, this series of randomised N-of-1 trials found no overall effect of statins on muscle symptoms compared with the placebo. The slight difference in withdrawals due to muscle symptoms suggests that statins may contribute to symptoms in a small number of patients. The results are generalisable to patients who are considering discontinuing or have already discontinued statins because of muscle symptoms, and who are willing to re-challenge or participate in their own N-of-1 trial.
We recommend that additional statins and doses are explored using N-of-1 trials. More broadly, N-of-1 trials present a useful tool for exploring transient symptoms with other medications.
This study used 20-mg doses of atorvastatin only. Furthermore, a dropout rate of 43% was observed, but this was accounted for in the power calculations.
Current Controlled Trials ISRCTN30952488 and EudraCT 2016-000141-31.
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in
; Vol. 25, No. 16. See the NIHR Journals Library website for further project information. |
|---|---|
| AbstractList | Statins are one of the most commonly prescribed drugs in the UK. There is strong evidence that they are effective in safely reducing heart disease; however, there is some doubt about whether or not statins cause muscle pain, stiffness or weakness. This research has been carried out to understand the effect of statins on muscle symptoms. To answer our question, we asked 200 volunteers from across England and Wales to participate in the study. Patients who joined the study either had recently stopped taking statins because of muscle symptoms or were considering stopping because of muscle symptoms. Patients who participated were randomly assigned to a sequence of six 2-month treatment periods during which they received either statins or a placebo. Neither patients nor their general practitioner knew which tablet they were receiving. This helped to reduce bias in the data. At the end of each treatment period, patients were asked to report any muscle symptoms, or any other symptoms, that they experienced. The key result of this work is that patients reported no difference, on average, in their muscle symptoms between periods of taking a statin and periods of taking a placebo. We also assessed the impact on the patient’s quality of life by looking at how statins affected the following areas: general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. As with muscle symptoms, there was no evidence of a difference between statin and placebo periods. The majority of patients who finished the trial decided to continue using statins after the trial. Future research should be carried out to assess different statin doses, as higher doses are often used following a heart attack. In addition, further work is needed to see how the approach we used could be adopted into everyday clinical care. Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis.BACKGROUNDUncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis.To establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin related.OBJECTIVESTo establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin related.A series of 200 double-blinded N-of-1 trials.DESIGNA series of 200 double-blinded N-of-1 trials.Participants were recruited from 50 general practices in England and Wales.SETTINGParticipants were recruited from 50 general practices in England and Wales.Patients who were considering discontinuing statin use and those who had discontinued statin use in the last 3 years because of perceived muscle symptoms.PARTICIPANTSPatients who were considering discontinuing statin use and those who had discontinued statin use in the last 3 years because of perceived muscle symptoms.Participants were randomised to a sequence of six 2-month treatment periods during which they received 20 mg of atorvastatin daily or a matched placebo.INTERVENTIONSParticipants were randomised to a sequence of six 2-month treatment periods during which they received 20 mg of atorvastatin daily or a matched placebo.The primary outcome was self-reported muscle symptoms rated using a visual analogue scale on the last week of each treatment period. Secondary outcomes included the participant's belief about the cause of their muscle symptoms, the site of muscle symptoms, how the muscle symptoms affected the participant, any other symptoms they experienced, adherence to medication, the participant's decision about statin treatment following the trial, and whether or not they found their own trial result helpful.MAIN OUTCOME MEASURESThe primary outcome was self-reported muscle symptoms rated using a visual analogue scale on the last week of each treatment period. Secondary outcomes included the participant's belief about the cause of their muscle symptoms, the site of muscle symptoms, how the muscle symptoms affected the participant, any other symptoms they experienced, adherence to medication, the participant's decision about statin treatment following the trial, and whether or not they found their own trial result helpful.A total of 151 out of 200 (75.5%) randomised participants provided one or more visual analogue scale measurements in a placebo period and one or more measurements in a statin period, and were included in the primary analysis. There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; p = 0.398). Withdrawals, adherence and missing data were similar during the statin periods and the placebo periods.RESULTSA total of 151 out of 200 (75.5%) randomised participants provided one or more visual analogue scale measurements in a placebo period and one or more measurements in a statin period, and were included in the primary analysis. There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; p = 0.398). Withdrawals, adherence and missing data were similar during the statin periods and the placebo periods.Among people who previously reported severe muscle symptoms while taking statins, this series of randomised N-of-1 trials found no overall effect of statins on muscle symptoms compared with the placebo. The slight difference in withdrawals due to muscle symptoms suggests that statins may contribute to symptoms in a small number of patients. The results are generalisable to patients who are considering discontinuing or have already discontinued statins because of muscle symptoms, and who are willing to re-challenge or participate in their own N-of-1 trial.CONCLUSIONSAmong people who previously reported severe muscle symptoms while taking statins, this series of randomised N-of-1 trials found no overall effect of statins on muscle symptoms compared with the placebo. The slight difference in withdrawals due to muscle symptoms suggests that statins may contribute to symptoms in a small number of patients. The results are generalisable to patients who are considering discontinuing or have already discontinued statins because of muscle symptoms, and who are willing to re-challenge or participate in their own N-of-1 trial.We recommend that additional statins and doses are explored using N-of-1 trials. More broadly, N-of-1 trials present a useful tool for exploring transient symptoms with other medications.FUTURE WORKWe recommend that additional statins and doses are explored using N-of-1 trials. More broadly, N-of-1 trials present a useful tool for exploring transient symptoms with other medications.This study used 20-mg doses of atorvastatin only. Furthermore, a dropout rate of 43% was observed, but this was accounted for in the power calculations.LIMITATIONSThis study used 20-mg doses of atorvastatin only. Furthermore, a dropout rate of 43% was observed, but this was accounted for in the power calculations.Current Controlled Trials ISRCTN30952488 and EudraCT 2016-000141-31.TRIAL REGISTRATIONCurrent Controlled Trials ISRCTN30952488 and EudraCT 2016-000141-31.This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 16. See the NIHR Journals Library website for further project information.FUNDINGThis project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 16. See the NIHR Journals Library website for further project information. Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis. To establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin related. A series of 200 double-blinded N-of-1 trials. Participants were recruited from 50 general practices in England and Wales. Patients who were considering discontinuing statin use and those who had discontinued statin use in the last 3 years because of perceived muscle symptoms. Participants were randomised to a sequence of six 2-month treatment periods during which they received 20 mg of atorvastatin daily or a matched placebo. The primary outcome was self-reported muscle symptoms rated using a visual analogue scale on the last week of each treatment period. Secondary outcomes included the participant's belief about the cause of their muscle symptoms, the site of muscle symptoms, how the muscle symptoms affected the participant, any other symptoms they experienced, adherence to medication, the participant's decision about statin treatment following the trial, and whether or not they found their own trial result helpful. A total of 151 out of 200 (75.5%) randomised participants provided one or more visual analogue scale measurements in a placebo period and one or more measurements in a statin period, and were included in the primary analysis. There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; = 0.398). Withdrawals, adherence and missing data were similar during the statin periods and the placebo periods. Among people who previously reported severe muscle symptoms while taking statins, this series of randomised N-of-1 trials found no overall effect of statins on muscle symptoms compared with the placebo. The slight difference in withdrawals due to muscle symptoms suggests that statins may contribute to symptoms in a small number of patients. The results are generalisable to patients who are considering discontinuing or have already discontinued statins because of muscle symptoms, and who are willing to re-challenge or participate in their own N-of-1 trial. We recommend that additional statins and doses are explored using N-of-1 trials. More broadly, N-of-1 trials present a useful tool for exploring transient symptoms with other medications. This study used 20-mg doses of atorvastatin only. Furthermore, a dropout rate of 43% was observed, but this was accounted for in the power calculations. Current Controlled Trials ISRCTN30952488 and EudraCT 2016-000141-31. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 25, No. 16. See the NIHR Journals Library website for further project information. Background: Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis. Objectives: To establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin related. Design: A series of 200 double-blinded N-of-1 trials. Setting: Participants were recruited from 50 general practices in England and Wales. Participants: Patients who were considering discontinuing statin use and those who had discontinued statin use in the last 3 years because of perceived muscle symptoms. Interventions: Participants were randomised to a sequence of six 2-month treatment periods during which they received 20 mg of atorvastatin daily or a matched placebo. Main outcome measures: The primary outcome was self-reported muscle symptoms rated using a visual analogue scale on the last week of each treatment period. Secondary outcomes included the participant’s belief about the cause of their muscle symptoms, the site of muscle symptoms, how the muscle symptoms affected the participant, any other symptoms they experienced, adherence to medication, the participant’s decision about statin treatment following the trial, and whether or not they found their own trial result helpful. Results: A total of 151 out of 200 (75.5%) randomised participants provided one or more visual analogue scale measurements in a placebo period and one or more measurements in a statin period, and were included in the primary analysis. There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo –0.11, 95% confidence interval –0.36 to 0.14; p = 0.398). Withdrawals, adherence and missing data were similar during the statin periods and the placebo periods. Conclusions: Among people who previously reported severe muscle symptoms while taking statins, this series of randomised N-of-1 trials found no overall effect of statins on muscle symptoms compared with the placebo. The slight difference in withdrawals due to muscle symptoms suggests that statins may contribute to symptoms in a small number of patients. The results are generalisable to patients who are considering discontinuing or have already discontinued statins because of muscle symptoms, and who are willing to re-challenge or participate in their own N-of-1 trial. Future work: We recommend that additional statins and doses are explored using N-of-1 trials. More broadly, N-of-1 trials present a useful tool for exploring transient symptoms with other medications. Limitations: This study used 20-mg doses of atorvastatin only. Furthermore, a dropout rate of 43% was observed, but this was accounted for in the power calculations. Trial registration: Current Controlled Trials ISRCTN30952488 and EudraCT 2016-000141-31. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 16. See the NIHR Journals Library website for further project information. |
| Author | Williamson, Elizabeth Prowse, Danielle Armitage, Jane Beaumont, Danielle Herrett, Emily Goldacre, Ben van Staa, Tjeerd Moore, Michael Shakur-Still, Haleema MacDonald, Thomas M Perkins, Alexander Roberts, Ian Smeeth, Liam Jamal, Zahra Hoffman, Maurice Thayne, Andrew Brack, Kieran |
| Author_xml | – sequence: 1 givenname: Emily orcidid: 0000-0002-9425-644X surname: Herrett fullname: Herrett, Emily organization: Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 2 givenname: Elizabeth orcidid: 0000-0001-6905-876X surname: Williamson fullname: Williamson, Elizabeth organization: Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK – sequence: 3 givenname: Kieran orcidid: 0000-0002-8100-8949 surname: Brack fullname: Brack, Kieran organization: Liver Research, King’s College Hospital, London, UK – sequence: 4 givenname: Alexander orcidid: 0000-0002-9817-2390 surname: Perkins fullname: Perkins, Alexander organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 5 givenname: Andrew orcidid: 0000-0002-9702-1662 surname: Thayne fullname: Thayne, Andrew organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 6 givenname: Haleema orcidid: 0000-0002-6511-109X surname: Shakur-Still fullname: Shakur-Still, Haleema organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 7 givenname: Ian orcidid: 0000-0003-1596-6054 surname: Roberts fullname: Roberts, Ian organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 8 givenname: Danielle orcidid: 0000-0002-7470-4823 surname: Prowse fullname: Prowse, Danielle organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 9 givenname: Danielle orcidid: 0000-0002-2530-9608 surname: Beaumont fullname: Beaumont, Danielle organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 10 givenname: Zahra orcidid: 0000-0002-3817-6795 surname: Jamal fullname: Jamal, Zahra organization: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK – sequence: 11 givenname: Ben orcidid: 0000-0002-5127-4728 surname: Goldacre fullname: Goldacre, Ben organization: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK – sequence: 12 givenname: Tjeerd orcidid: 0000-0001-9363-742X surname: van Staa fullname: van Staa, Tjeerd organization: Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK – sequence: 13 givenname: Thomas M orcidid: 0000-0001-5189-6669 surname: MacDonald fullname: MacDonald, Thomas M organization: Medicines Monitoring Unit, School of Medicine, University of Dundee, Dundee, UK – sequence: 14 givenname: Jane orcidid: 0000-0001-8691-9226 surname: Armitage fullname: Armitage, Jane organization: Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK – sequence: 15 givenname: Michael orcidid: 0000-0002-5127-4509 surname: Moore fullname: Moore, Michael organization: School of Primary Care and Population Sciences, University of Southampton, Southampton, UK – sequence: 16 givenname: Maurice orcidid: 0000-0002-8860-4786 surname: Hoffman fullname: Hoffman, Maurice organization: London, UK – sequence: 17 givenname: Liam orcidid: 0000-0002-9168-6022 surname: Smeeth fullname: Smeeth, Liam organization: Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33709907$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkV1rFDEUhoNU7LYK_gLJpTdT850ZLwRZqi4UBbvgZcgkJ92UmcmaZIX-e2e322r16kDOc55zwnuGTqY0AUKvKbngnJJ3m2qZpIo8QwtGhGpEx8QJWlCuVCOZbk_RWSm3hAiqJH2BTjnXpOuIXqB-vQEMIYCrOAVcqq1xKjhNeNwVNwAud-O2prHgOOFtjqPNd9jZDO9xnSevD_yP1fUlLpAjlL2EEYK_Nik0FH9frstL9DzYocCrYz1H60-X6-WX5urb59Xy41XjBG9r46D1TgsblJK2A9kyy1qmSN97T7wGrUTorVbeMaK8tloA9EIq4phWmvBztLrX-mRvzfFUk2w0h4eUb4zNNc5_MrZjyvnOS8mF6FTbCtc67gNzmtnQqdn14d613fUjeAdTzXZ4In3ameLG3KRfpiWM0IPg7VGQ088dlGrGWBwMg50g7YphklAmNe_YjL75e9fjkoeM_rhcTqVkCI8IJWYfv3mIf0Yv_kFd3CeU9lfG4f-B3yKxsIs |
| CitedBy_id | crossref_primary_10_1007_s40290_022_00448_6 crossref_primary_10_1016_j_numecd_2023_08_011 crossref_primary_10_1002_cpt_3208 |
| Cites_doi | 10.1136/bmj.f6123 10.7326/M18-0808 10.5694/mja15.00103 10.1161/CIRCULATIONAHA.106.624890 10.1016/S0140-6736(16)31357-5 10.1371/journal.pone.0028124 10.1056/NEJM198604033141406 10.1016/S0197-2456(97)00008-1 10.1016/S0140-6736(11)60739-3 10.1016/S1567-5688(17)30024-7 10.1001/jama.287.5.622 10.1371/journal.pmed.1001526 10.1016/S0140-6736(02)09327-3 10.1136/bmj.i3305 10.1016/j.ahj.2013.06.004 10.1016/S0140-6736(17)31075-9 10.1093/eurheartj/ehv641 10.1056/NEJMoa0706201 10.1093/bja/aen103 10.1016/j.jacl.2012.03.003 10.1136/bmj.f6340 10.1136/bmjopen-2017-016604 10.1067/mem.2001.118863 10.1056/NEJMc2031173 10.1016/j.jacl.2015.08.006 10.1111/j.1553-2712.1996.tb03402.x 10.1016/j.ahj.2016.01.016 10.1186/1741-7015-12-51 10.1097/JCN.0b013e3181ae7b2a 10.1136/bmj.i3283 10.1093/oxfordjournals.eurheartj.a060485 10.1111/bcp.12339 10.1093/eurheartj/ehv043 10.1136/bmj.n135 10.7326/M16-0838 10.1016/S0140-6736(14)61368-4 10.1017/s0033291700009934 10.7326/0003-4819-158-7-201304020-00004 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3310/hta25160 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2046-4924 |
| EndPage | 62 |
| ExternalDocumentID | oai_doaj_org_article_a926cd9d5534496884c8c3df2c72af96 PMC8020196 33709907 10_3310_hta25160 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | England |
| GeographicLocations_xml | – name: England |
| GrantInformation | Vol. 25, No. 16. See the NIHR Journals Library website for further project information. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in |
| GrantInformation_xml | – fundername: Department of Health grantid: 14/49/159 |
| GroupedDBID | --- 53G 5GY AAYXX ADBBV ADDVE AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CITATION CZQ DIK EBS EJD F5P GROUPED_DOAJ OK1 P2P P6G TR2 W2D CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c438t-ce8dc74af665a9e582a28260bbdd0d7e764fba76dc206d7a74eeb4560c276703 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000628648800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1366-5278 2046-4924 |
| IngestDate | Fri Oct 03 12:53:13 EDT 2025 Thu Aug 21 14:36:00 EDT 2025 Fri Jul 11 11:59:30 EDT 2025 Thu Jan 02 22:42:21 EST 2025 Tue Nov 18 20:26:07 EST 2025 Sat Nov 29 03:04:27 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Keywords | CHOLESTEROL CARDIOVASCULAR DISEASES PRIMARY HEALTH CARE VISUAL ANALOGUE SCALE GENERAL PRACTITIONERS MEDICATION ADHERENCE MUSCLE PAIN SECONDARY PREVENTION ATORVASTATIN |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c438t-ce8dc74af665a9e582a28260bbdd0d7e764fba76dc206d7a74eeb4560c276703 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-9702-1662 0000-0002-7470-4823 0000-0002-3817-6795 0000-0002-6511-109X 0000-0002-5127-4509 0000-0001-9363-742X 0000-0001-8691-9226 0000-0002-8860-4786 0000-0001-5189-6669 0000-0002-5127-4728 0000-0001-6905-876X 0000-0002-2530-9608 0000-0002-9168-6022 0000-0002-9425-644X 0000-0003-1596-6054 0000-0002-9817-2390 0000-0002-8100-8949 |
| OpenAccessLink | https://doaj.org/article/a926cd9d5534496884c8c3df2c72af96 |
| PMID | 33709907 |
| PQID | 2501257392 |
| PQPubID | 23479 |
| PageCount | 62 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a926cd9d5534496884c8c3df2c72af96 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8020196 proquest_miscellaneous_2501257392 pubmed_primary_33709907 crossref_primary_10_3310_hta25160 crossref_citationtrail_10_3310_hta25160 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-01 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Health technology assessment (Winchester, England) |
| PublicationTitleAlternate | Health Technol Assess |
| PublicationYear | 2021 |
| Publisher | NIHR Journals Library |
| Publisher_xml | – name: NIHR Journals Library |
| References | Todd (key20210311102816163_ref1-bib29) 1996; 3 Herrett (key20210311102816163_ref1-bib25) 2017; 7 Mampuya (key20210311102816163_ref1-bib40) 2013; 166 Gallagher (key20210311102816163_ref1-bib30) 2001; 38 De Vera (key20210311102816163_ref1-bib14) 2014; 78 key20210311102816163_ref1-bib26 Pocock (key20210311102816163_ref1-bib34) 1997; 18 McCormack (key20210311102816163_ref1-bib27) 1988; 18 Cohen (key20210311102816163_ref1-bib31) 2012; 6 Fulcher (key20210311102816163_ref1-bib2) 2015; 385 Schaffer (key20210311102816163_ref1-bib10) 2015; 202 Gupta (key20210311102816163_ref1-bib38) 2017; 389 Nielsen (key20210311102816163_ref1-bib9) 2016; 37 Wieseler (key20210311102816163_ref1-bib17) 2013; 10 Laufs (key20210311102816163_ref1-bib23) 2017; 26 Abramson (key20210311102816163_ref1-bib5) 2013; 347 Garavalia (key20210311102816163_ref1-bib8) 2009; 24 Vinogradova (key20210311102816163_ref1-bib13) 2016; 353 Baigent (key20210311102816163_ref1-bib20) 2011; 377 Guyatt (key20210311102816163_ref1-bib24) 1986; 314 Macedo (key20210311102816163_ref1-bib37) 2014; 12 Wood (key20210311102816163_ref1-bib35) 2020; 383 Breivik (key20210311102816163_ref1-bib33) 2008; 101 Herrett (key20210311102816163_ref1-bib1) 2021; 372 American College of Cardiology (key20210311102816163_ref1-bib22) Kashani (key20210311102816163_ref1-bib16) 2006; 114 Moriarty (key20210311102816163_ref1-bib15) 2015; 9 Zhang (key20210311102816163_ref1-bib39) 2017; 167 Collins (key20210311102816163_ref1-bib4) 2016; 388 Stroes (key20210311102816163_ref1-bib21) 2015; 36 Heart Protection Study Collaborative Group (key20210311102816163_ref1-bib19) 2002; 360 Cholesterol Treatment Trialists’ Collaboration (key20210311102816163_ref1-bib36) 2016; 176 Cholesterol Treatment Trialists’ Collaboration (key20210311102816163_ref1-bib3) 2016; 393 Matthews (key20210311102816163_ref1-bib11) 2016; 353 Kjekshus (key20210311102816163_ref1-bib18) 2007; 357 Keech (key20210311102816163_ref1-bib32) 1994; 15 Malhotra (key20210311102816163_ref1-bib6) 2013; 347 Barsky (key20210311102816163_ref1-bib12) 2002; 287 Zhang (key20210311102816163_ref1-bib7) 2013; 158 Sakaeda (key20210311102816163_ref1-bib28) 2011; 6 He (key20210311102816163_ref1-bib41) 2018; 169 |
| References_xml | – volume: 347 start-page: f6123 year: 2013 ident: key20210311102816163_ref1-bib5 article-title: Should people at low risk of cardiovascular disease take a statin? publication-title: BMJ doi: 10.1136/bmj.f6123 – volume: 169 start-page: 543 year: 2018 ident: key20210311102816163_ref1-bib41 article-title: Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials publication-title: Ann Intern Med doi: 10.7326/M18-0808 – volume: 202 start-page: 591 year: 2015 ident: key20210311102816163_ref1-bib10 article-title: The crux of the matter: did the ABC’s catalyst program change statin use in Australia? publication-title: Med J Aust doi: 10.5694/mja15.00103 – volume: 114 start-page: 2788 year: 2006 ident: key20210311102816163_ref1-bib16 article-title: Risks associated with statin therapy: a systematic overview of randomized clinical trials publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.624890 – volume: 388 start-page: 2532 year: 2016 ident: key20210311102816163_ref1-bib4 article-title: Interpretation of the evidence for the efficacy and safety of statin therapy publication-title: Lancet doi: 10.1016/S0140-6736(16)31357-5 – volume: 6 start-page: e28124 year: 2011 ident: key20210311102816163_ref1-bib28 article-title: Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system publication-title: PLOS ONE doi: 10.1371/journal.pone.0028124 – volume: 314 start-page: 889 year: 1986 ident: key20210311102816163_ref1-bib24 article-title: Determining optimal therapy – randomized trials in individual patients publication-title: N Engl J Med doi: 10.1056/NEJM198604033141406 – volume: 18 start-page: 530 year: 1997 ident: key20210311102816163_ref1-bib34 article-title: Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation publication-title: Controlled Clin Trials doi: 10.1016/S0197-2456(97)00008-1 – volume: 377 start-page: 2181 year: 2011 ident: key20210311102816163_ref1-bib20 article-title: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(11)60739-3 – volume: 26 start-page: 45 year: 2017 ident: key20210311102816163_ref1-bib23 article-title: Practical aspects in the management of statin-associated muscle symptoms (SAMS) publication-title: Atheroscler Suppl doi: 10.1016/S1567-5688(17)30024-7 – volume: 287 start-page: 622 year: 2002 ident: key20210311102816163_ref1-bib12 article-title: Nonspecific medication side effects and the nocebo phenomenon publication-title: JAMA doi: 10.1001/jama.287.5.622 – volume: 10 start-page: e1001526 year: 2013 ident: key20210311102816163_ref1-bib17 article-title: Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data publication-title: PLOS Med doi: 10.1371/journal.pmed.1001526 – volume-title: Statin Intolerance Tool ident: key20210311102816163_ref1-bib22 – volume: 360 start-page: 7 year: 2002 ident: key20210311102816163_ref1-bib19 article-title: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(02)09327-3 – volume: 353 start-page: i3305 year: 2016 ident: key20210311102816163_ref1-bib13 article-title: Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database publication-title: BMJ doi: 10.1136/bmj.i3305 – volume: 166 start-page: 597 year: 2013 ident: key20210311102816163_ref1-bib40 article-title: Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience publication-title: Am Heart J doi: 10.1016/j.ahj.2013.06.004 – volume: 389 start-page: 2473 year: 2017 ident: key20210311102816163_ref1-bib38 article-title: Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase publication-title: Lancet doi: 10.1016/S0140-6736(17)31075-9 – volume: 37 start-page: 908 year: 2016 ident: key20210311102816163_ref1-bib9 article-title: Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv641 – volume: 357 start-page: 2248 year: 2007 ident: key20210311102816163_ref1-bib18 article-title: Rosuvastatin in older patients with systolic heart failure publication-title: N Engl J Med doi: 10.1056/NEJMoa0706201 – volume: 101 start-page: 17 year: 2008 ident: key20210311102816163_ref1-bib33 article-title: Assessment of pain publication-title: Br J Anaesth doi: 10.1093/bja/aen103 – volume: 6 start-page: 208 year: 2012 ident: key20210311102816163_ref1-bib31 article-title: Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2012.03.003 – volume: 347 start-page: f6340 year: 2013 ident: key20210311102816163_ref1-bib6 article-title: Saturated fat is not the major issue publication-title: BMJ doi: 10.1136/bmj.f6340 – volume: 7 start-page: e016604 year: 2017 ident: key20210311102816163_ref1-bib25 article-title: Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care publication-title: BMJ Open doi: 10.1136/bmjopen-2017-016604 – ident: key20210311102816163_ref1-bib26 – volume: 38 start-page: 633 year: 2001 ident: key20210311102816163_ref1-bib30 article-title: Prospective validation of clinically important changes in pain severity measured on a visual analog scale publication-title: Ann Emerg Med doi: 10.1067/mem.2001.118863 – volume: 383 start-page: 2182 year: 2020 ident: key20210311102816163_ref1-bib35 article-title: N-of-1 trial of a statin, placebo, or no treatment to assess side effects publication-title: N Engl J Med doi: 10.1056/NEJMc2031173 – volume: 9 start-page: 758 year: 2015 ident: key20210311102816163_ref1-bib15 article-title: Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2015.08.006 – volume: 3 start-page: 142 year: 1996 ident: key20210311102816163_ref1-bib29 article-title: The minimum clinically important difference in physician-assigned visual analog pain scores publication-title: Acad Emerg Med doi: 10.1111/j.1553-2712.1996.tb03402.x – volume: 176 start-page: 63 year: 2016 ident: key20210311102816163_ref1-bib36 article-title: Protocol for analyses of adverse event data from randomized controlled trials of statin therapy publication-title: Am Heart J doi: 10.1016/j.ahj.2016.01.016 – volume: 12 start-page: 51 year: 2014 ident: key20210311102816163_ref1-bib37 article-title: Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis publication-title: BMC Med doi: 10.1186/1741-7015-12-51 – volume: 24 start-page: 371 year: 2009 ident: key20210311102816163_ref1-bib8 article-title: Exploring patients’ reasons for discontinuance of heart medications publication-title: J Cardiovasc Nurs doi: 10.1097/JCN.0b013e3181ae7b2a – volume: 353 start-page: i3283 year: 2016 ident: key20210311102816163_ref1-bib11 article-title: Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data publication-title: BMJ doi: 10.1136/bmj.i3283 – volume: 15 start-page: 255 year: 1994 ident: key20210311102816163_ref1-bib32 article-title: Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study publication-title: Eur Heart J doi: 10.1093/oxfordjournals.eurheartj.a060485 – volume: 78 start-page: 684 year: 2014 ident: key20210311102816163_ref1-bib14 article-title: Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12339 – volume: 36 start-page: 1012 year: 2015 ident: key20210311102816163_ref1-bib21 article-title: Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv043 – volume: 372 start-page: N135 year: 2021 ident: key20210311102816163_ref1-bib1 article-title: Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials publication-title: BMJ doi: 10.1136/bmj.n135 – volume: 167 start-page: 221 year: 2017 ident: key20210311102816163_ref1-bib39 article-title: Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study publication-title: Ann Intern Med doi: 10.7326/M16-0838 – volume: 385 start-page: 1397 year: 2015 ident: key20210311102816163_ref1-bib2 article-title: Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(14)61368-4 – volume: 18 start-page: 1007 year: 1988 ident: key20210311102816163_ref1-bib27 article-title: Clinical applications of visual analogue scales: a critical review publication-title: Psychol Med doi: 10.1017/s0033291700009934 – volume: 393 start-page: 407 year: 2016 ident: key20210311102816163_ref1-bib3 article-title: Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials publication-title: Lancet – volume: 158 start-page: 526 year: 2013 ident: key20210311102816163_ref1-bib7 article-title: Discontinuation of statins in routine care settings: a cohort study publication-title: Ann Intern Med doi: 10.7326/0003-4819-158-7-201304020-00004 |
| SSID | ssj0041651 |
| Score | 2.3553436 |
| Snippet | Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe... Statins are one of the most commonly prescribed drugs in the UK. There is strong evidence that they are effective in safely reducing heart disease; however,... Background: Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1 |
| SubjectTerms | atorvastatin cardiovascular diseases cholesterol Cost-Benefit Analysis England - epidemiology general practitioners Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects medication adherence muscle pain Muscles Primary Health Care secondary prevention Technology Assessment, Biomedical visual analogue scale |
| Title | The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33709907 https://www.proquest.com/docview/2501257392 https://pubmed.ncbi.nlm.nih.gov/PMC8020196 https://doaj.org/article/a926cd9d5534496884c8c3df2c72af96 |
| Volume | 25 |
| WOSCitedRecordID | wos000628648800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2046-4924 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041651 issn: 1366-5278 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7aUEovIekr2zxQodCTiFeW9cgtCQkJtEtpFro3I-tBFrJ2iL2F_vuOZO82WwK99GrJljQz1nzDjD4BfNIYmTBtMoruO9BIQEeVc4GGgimTjX2mXKLM_yInEzWb6W-PrvqKNWE9PXAvuGOjmbBOu6LIOddCKW6VzV1gVjITdCLbRtSzCqb6PRhRRjGcuBIYaknV087miGWObzuDPj1RUv5xRImv_ymQ-Xet5CPnc7kD2wNqJKf9bHfhma9fw8uvQ178DVSobdKXZpAmkHhKaF63pKnJYtniG6T9tbjvmkVL5jW57wkmSCz6OiEIAMlN6v_j-uaCRIv0bfwIGjaZ0CbQMfl-Pm3fwvTyYnp-RYfbE6jlueqo9cpZyU0QojDaF4oZDK9EVlXOZU56KXiojBTOskw4aST3vkI4lVkmBe4D72Crbmq_BySEQmsucu6V5sb5KhLkKDEOBQZwnPERfF5JsrQDs3i84OKuxAgjyrxcyXwEH9c9h8U-0ecsKmPdHvmv0wO0inKwivJfVoEDrVRZ4v8SkyCm9s2yLRHyIaaTCAtH8L5X7XqoPJcxTyhHIDeUvjGXzZZ6fps4uRXCbtzMPvyPye_DKxYrZ1Kl2wFsdQ9Lfwgv7M9u3j4cwXM5U0fJ3H8DmV0BhA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+statins+on+muscle+symptoms+in+primary+care%3A+the+StatinWISE+series+of+200+N-of-1+RCTs&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=Emily+Herrett&rft.au=Elizabeth+Williamson&rft.au=Kieran+Brack&rft.au=Alexander+Perkins&rft.date=2021-03-01&rft.pub=NIHR+Journals+Library&rft.issn=1366-5278&rft.eissn=2046-4924&rft.volume=25&rft.issue=16&rft_id=info:doi/10.3310%2Fhta25160&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a926cd9d5534496884c8c3df2c72af96 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1366-5278&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1366-5278&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1366-5278&client=summon |